Scholarlink

<p>Residual excessive daytime sleepiness (EDS) may be seen in patients with obstructive sleep apnea (OSA) despite compliance with continuous positive airway pressure (CPAP) therapy. Residual EDS can be detrimental as it may impact cognitive performance and quality of life (QOL); hence, it should be evaluated to exclude other causes of EDS, such as hypothyroidism, narcolepsy and idiopathic hypersomnia. Once these have been ruled out, pharmacotherapy should be initiated. Various wake-promoting agents are currently available, such as modafinil/armodafinil, solriamfetol and pitolisant. This review provides updated evidence of currently available pharmacotherapy for EDS and the order of selection of various drugs. Pitolisant and solriamfetol were found to have similar efficacy. However, pitolisant has a better safety profile and should be considered as the first choice, especially in patients with cardiac comorbidities. Modafinil and armodafinil, although more economical, are less efficacious.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacotherapy for Excessive Daytime Sleepiness in Obstructive Sleep Apnea Despite Positive Airway Pressure: Evidence and Current Status

  • 期刊论文

  • 发表日期：

    2025年4月3日

查看全文
  • Sanchit Mohan,
  • Rohit Kumar,
  • Nitesh Gupta,
  • Pranav Ish

摘要

Residual excessive daytime sleepiness (EDS) may be seen in patients with obstructive sleep apnea (OSA) despite compliance with continuous positive airway pressure (CPAP) therapy. Residual EDS can be detrimental as it may impact cognitive performance and quality of life (QOL); hence, it should be evaluated to exclude other causes of EDS, such as hypothyroidism, narcolepsy and idiopathic hypersomnia. Once these have been ruled out, pharmacotherapy should be initiated. Various wake-promoting agents are currently available, such as modafinil/armodafinil, solriamfetol and pitolisant. This review provides updated evidence of currently available pharmacotherapy for EDS and the order of selection of various drugs. Pitolisant and solriamfetol were found to have similar efficacy. However, pitolisant has a better safety profile and should be considered as the first choice, especially in patients with cardiac comorbidities. Modafinil and armodafinil, although more economical, are less efficacious.